QIAGEN Reports First Quarter 2011 Results
. - Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other ma…
. - Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other ma…
AiCuris announced today that AIC246, the Company's inhibitor against the human cytomegalovirus HCMV, currently undergoin…
. - QIAGEN to acquire Cellestis Limited (CST:AU) via a Scheme of Arrangement (the Scheme) for approximately A$341 milli…
AiCuris announced today that its novel HCMV inhibitor AIC246 has been used successfully to treat a patient with multi-or…
Wie AiCuris heute mitteilte, wird am 23. Oktober 2010 auf der 48. IDSA Konferenz die erfolgreiche Behandlung einer multi…
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into…
ProBioGen AG, a leading biotechnology company in cell engineering and production of biopharmaceuticals, today announced…
ProBioGen AG, ein führendes Biotechnologieunternehmen in den Bereichen Zellliniendesign und Herstellung von Biopharmaze…
Die Fakten sind alarmierend: Eine Cytomegalie-Infektion ist die häufigste Virus-Erkrankung in der Schwangerschaft und ka…
/pressemitteilung/pdf/48202/meldung.pdf